top of page
OUR TEAM
Our outstanding management team, supported by the board of directors and scientific advisory board, is dedicated to developing our core pipeline products that target diseases and conditions affecting women’s health.
Executive Team
Craig R. Travis, M.D., CEO and President
Craig R. Travis, M.D. is the Founder, CEO and President
In the more than 40 years that Dr. Travis had been a practicing board-certified emergency physician, the six years he spent in Negril Jamaica (1988-1994)
In the more than 40 years that Dr. Travis had been a practicing board-certified emergency physician, the six years he spent in Negril Jamaica (1988-1994)
Elizabeth Fenjves, Ph.D., Chief Scientific Officer
Former Director of Innovation Office (Technology Transfer)
University of Miami
Her doctoral and post-doctoral work focused on epithelial gene therapy and she later contributed to research at the University of Miami’s Diabetes Research Institute.
Currently CEO of i2M & Telehealth Consultant
University of Miami
Her doctoral and post-doctoral work focused on epithelial gene therapy and she later contributed to research at the University of Miami’s Diabetes Research Institute.
Currently CEO of i2M & Telehealth Consultant
Dessi McEntee, MS, DABT -
Chief Development Officer
Dessi McEntee, MS, DABT is a board-certified toxicologist and drug development strategist with over 15 years of experience leading nonclinical programs from discovery through IND and into early clinical development. As the founder of Toxistrategy LLC, she serves as an embedded fractional executive for biotech and pharmaceutical companies, providing senior nonclinical leadership across small molecules, biologics, ADCs, vaccines, nanoparticles, and radiopharmaceuticals. Her work spans a broad range of therapeutic areas including oncology, immunology, autoimmune disease, rare disease, CNS, endocrine, and cardiovascular disorders.
Dessi brings an integrated command of science, regulatory strategy, and drug development operations. She provides end-to-end leadership across nonclinical safety strategy, CRO selection and management, IND authoring and submissions, pIND and briefing book preparation, SEND compliance, and cross-functional team integration. Her ability to translate complex nonclinical data into regulatory-defensible narratives has supported programs at some of the industry’s most respected companies, including Pfizer, Epizyme, Q32 Bio, and Instem.
Dessi is also the founder and former CEO of Mimicry Solutions, a biotechnology venture developing ARTEMIS™, an AI-driven computational toxicology platform designed to translate animal safety predictions into human outcomes. In this role she led algorithm development, authored patents, secured SBIR funding invitations, and built collaborations across academia, pharma, and AI/ML.
She is the author of three published works: Data Is Not Strategy: Why Interpretation, Not Volume, Drives Nonclinical Decisions (2025), Thank an Animal (2024), and Thank an Animal: Oncology (2024). She regularly publishes educational content through Toxistrategy’s newsletter and has developed curriculum for industry professionals seeking to deepen their nonclinical development expertise.
An active voice in the field, Dessi has delivered invited lectures and panel presentations at leading industry forums. Her speaking engagements include several panel discussions on faster study report delivery platforms and interim study monitoring at the as well as a webinar on interim study monitoring and submission-quality SEND dataset generation for PointCross Life Sciences. She contributes regularly to CDISC Core Teams and Safety Pharmacology Subteams, and is an active member of the Roundtable of Toxicology Consultants, ACT, SOT, ASCCT, and PHUSE.
Dessi holds an MS in Pharmacology and Toxicology from Michigan State University, a BS in Animal Science from the University of Connecticut, and earned her DABT certification in 2022.
Dessi brings an integrated command of science, regulatory strategy, and drug development operations. She provides end-to-end leadership across nonclinical safety strategy, CRO selection and management, IND authoring and submissions, pIND and briefing book preparation, SEND compliance, and cross-functional team integration. Her ability to translate complex nonclinical data into regulatory-defensible narratives has supported programs at some of the industry’s most respected companies, including Pfizer, Epizyme, Q32 Bio, and Instem.
Dessi is also the founder and former CEO of Mimicry Solutions, a biotechnology venture developing ARTEMIS™, an AI-driven computational toxicology platform designed to translate animal safety predictions into human outcomes. In this role she led algorithm development, authored patents, secured SBIR funding invitations, and built collaborations across academia, pharma, and AI/ML.
She is the author of three published works: Data Is Not Strategy: Why Interpretation, Not Volume, Drives Nonclinical Decisions (2025), Thank an Animal (2024), and Thank an Animal: Oncology (2024). She regularly publishes educational content through Toxistrategy’s newsletter and has developed curriculum for industry professionals seeking to deepen their nonclinical development expertise.
An active voice in the field, Dessi has delivered invited lectures and panel presentations at leading industry forums. Her speaking engagements include several panel discussions on faster study report delivery platforms and interim study monitoring at the as well as a webinar on interim study monitoring and submission-quality SEND dataset generation for PointCross Life Sciences. She contributes regularly to CDISC Core Teams and Safety Pharmacology Subteams, and is an active member of the Roundtable of Toxicology Consultants, ACT, SOT, ASCCT, and PHUSE.
Dessi holds an MS in Pharmacology and Toxicology from Michigan State University, a BS in Animal Science from the University of Connecticut, and earned her DABT certification in 2022.
bottom of page